Ash Shehata from KPMG discusses how artificial technology has a lot to prove, although investors still see a lot of potential in it.
The Ups and Downs of AI for Pharma Investors
You May Also Like
Where can I buy Tobacco-Free Nicotine products?
February 27, 2025
Ozempic 用於什麼？
February 26, 2025
Global Launch Strategies in the Current Political Climate
February 19, 2025
+ There are no comments
Add yours